TLR7 and primary cutaneous T-cell non-Hodgkin lymphoma: Resiquimod, also known as R848, is a small molecule agonist of both TLR7 and TLR8 that has been evaluated using a topical formulation in clinical trials for the treatment of cutaneous T cell lymphoma (CTCL) [7].